microXpace's mission is to put advanced microbial applications at the frontline of the 'One Health' initiative.
Please enter subscribe form shortcode
Please enter instagram feed shortcode
Giardia intestinalis is the protozoan responsible for giardiasis, a disease marked by intestinal malabsorption, diarrhea, weight loss, and intense abdominal pain in both humans and animals. This condition significantly impacts public health, with prevalence rates ranging from 2 to 7.5% in industrialized countries and 12 to 30% in developing nations. Giardiasis can lead to severe nutritional deficiencies, especially in young individuals. The disease is transmitted through the ingestion of cysts found in contaminated food or water. These cysts are infectious at very low doses, can survive for months in the environment, and are resistant to many disinfectants. The increasing incidence of giardiasis related to contaminated drinking water, significant treatment side effects, and the emergence of drug-resistant strains highlight the growing public health concern and underscore the need for alternative treatments.
The intestinal microbiota and certain probiotic bacteria strains play a crucial role in defense against various intestinal pathogens. In this context, researchers at microXpace have discovered a probiotic bacterium with a potent anti-Giardia effect, offering a promising alternative for treating giardiasis. This innovative treatment holds potential for both human and veterinary applications, addressing numerous cases of giardiasis reported in dogs, cats, cattle, and swine.
We utilize a unique patented technology that harnesses the protective properties of a specific Lactobacillus johnsonii strain, which is integral to our product's mechanism of action. This strain possesses the capability to express bile salt hydrolases (BSH), enzymes that break down bile salts. This breakdown creates an inhospitable environment for certain intestinal pathogens, such as Giardia intestinalis, effectively reducing their viability. The efficacy of this process has been demonstrated through extensive research conducted in vitro and as well as in preclinical and clinical trials. As a result, our product not only offers significant benefits for intestinal health but also reduces the incidence of infections. This particular strain of L. johnsonii is an exclusive property of microXpace and is classified as GRAS, ensuring its safety and effectiveness for use in both human and veterinary medicine.